SynthesisAntimicrobial resistance and infection control2022
Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis.
Synthesis in Antimicrobial resistance and infection control, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Cholera burden in Ghana: a systematic review and meta-analysis of prevalence, antimicrobial resistance and risk factors.International health · 2025Pooled it
- Serotype and antimicrobial susceptibility patterns of Vibrio cholerae in cholera outbreak areas of East and Central Oromia Region, Ethiopia, 2024.BMC infectious diseases · 2026Article
- Integrated Phenotypic and Genomic Analysis of Antimicrobial Resistance, Virulence, and Phylogeny inMicroorganisms · 2026Article
- Genome-wide investigation of outbreak-associatedFrontiers in microbiology · 2026Article
- Genomic characterization of clinical and environmentalFrontiers in microbiology · 2026Article
- A Fitness Burden Drives the Reversion of in vitro Acquired Doxycycline Resistance inInfection and drug resistance · 2026Article
- Antimicrobial Resistance in Sub-Saharan Africa: A Comprehensive Landscape Review.The American journal of tropical medicine and hygiene · 2025Review
- Vibrio cholerae endemic to the lower Rio Grande Delta segregate into urban and rural phylotypes.Scientific reports · 2025Article
- Emerging antibiotic resistance in Vibrio cholerae: a study of cholera prevalence and resistance patterns in Zambia's Copperbelt Province.BMC infectious diseases · 2025Article
- Epidemiological investigation of a cholera outbreak in Nepal-India border communities: Public health implications.IJID regions · 2025Article
- Loop-mediated isothermal amplification assays for the detection of antimicrobial resistance elements in Vibrio cholera.BMC bioinformatics · 2024Article
- Prevalence and antimicrobial susceptibility pattern of Vibrio cholerae isolates from cholera outbreak sites in Ethiopia.BMC public health · 2024Article
- Vibrio cholerae O1 and Escherichia coli O157:H7 from drinking water and wastewater in Addis Ababa, Ethiopia.BMC microbiology · 2024Article
- Cholera rages in Africa and the Middle East: A narrative review on challenges and solutions.Health science reports · 2024Review
- Trends and antibiotic susceptibility patterns of diarrhoeal pathogens - experience over 14 years in southern India.Access microbiology · 2024Article
- Evidence of Antibiotic Resistance and Virulence Factors in Environmental Isolates ofAntibiotics (Basel, Switzerland) · 2023Article
- Vibrio cholerae O1 associated with recent endemic cholera shows temporal changes in serotype, genotype, and drug-resistance patterns in Bangladesh.Gut pathogens · 2023Article
- Resistance ofFrontiers in pharmacology · 2023Review
- A systematic review and meta-analysis on antimicrobial resistance in marine bivalves.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVibrio cholerae O1/O139 were the predominant circulating serogroups exhibiting multi-drug resistance (MDR) during the cholera outbreak which led to cholera treatment failures.
objectiveThis meta-analysis aimed to evaluate the weighted pooled resistance (WPR) rates in V. cholerae O1/O139 isolates obtained from environmental samples.
methodsWe systematically searched the articles in PubMed, Scopus, and Embase (until January 2020). Subgroup analyses were then employed by publication year, geographic areas, and the quality of studies. Statistical analyses were conducted using STATA software (ver. 14.0).
resultsA total of 20 studies investigating 648 environmental V. cholerae O1/O139 isolates were analysed. The majority of the studies were originated from Asia (n = 9). In addition, a large number of studies (n = 15 i.e. 71.4%) included in the meta-analysis revealed the resistance to cotrimoxazole and ciprofloxacin. The WPR rates were as follows: cotrimoxazole 59%, erythromycin 28%, tetracycline 14%, doxycycline 5%, and ciprofloxacin 0%. There was increased resistance to nalidixic acid, cotrimoxazole, furazolidone, and tetracycline while a decreased resistance to amoxicillin, ciprofloxacin, erythromycin, chloramphenicol, ampicillin, streptomycin, and ceftriaxone was observed during the years 2000-2020. A significant decrease in the doxycycline and ciprofloxacin-resistance rates in V. cholerae O1/O139 isolates was reported over the years 2011-2020 which represents a decrease in 2001-2010 (p < 0.05).
conclusionsFluoroquinolones, gentamicin, ceftriaxone, doxycycline, kanamycin, and cefotaxime showed the highest effectiveness and the lowest resistance rate. However, the main interest is the rise of antimicrobial resistance in V. cholerae strains especially in low-income countries or endemic areas, and therefore, continuous surveillance, careful appropriate AST, and limitation on improper antibiotic usage are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.